Compare DexCom, Inc. (DXCM) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs ThredUp Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while ThredUp Inc trades at $2.48 (market cap $308.63M). The key difference: DexCom, Inc. is far larger — about 103.2× ThredUp Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, ThredUp Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and ThredUp Inc for 29 Days on average.
| DXCM | TDUP | |
|---|---|---|
Market Cap | $31.86B | $308.63M |
Volume | 3,607,070 | 3,024,364 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $9.41 |
52-Week Low | $54.84 | $2.12 |
Typical Hold Time | 62 Days | 29 Days |
Enterprise Value | $31.32B | $306.81M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
ThredUp (TDUP) trades at $2.48, up 11.71% in the last session, yet remains in a bearish technical trend. The company reported record Q2 2026 revenue of $90.8 million, up 17% year-over-year, but missed EPS estimates and cut full-year revenue guidance. Despite a high gross margin of 79.52%, it posted a net loss margin of -6.65% and negative ROE. Analyst consensus is 57% buy, but recent news highlights a fraud investigation and promotional headwinds.
The outlook is mixed: strong revenue growth and a dominant position in online resale offer upside, but persistent losses, weak guidance, and legal risks pose significant challenges. Investors should weigh the bullish analyst ratings against fundamental weaknesses and recent stock volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
